search

Active clinical trials for "Precursor Cell Lymphoblastic Leukemia-Lymphoma"

Results 41-50 of 1817

CAR-T Cells Combined With Dasatinib for Patients With Relapsed and/or Refractory B-cell Hematological...

Multiple Myeloma in RelapseMultiple Myeloma7 more

A Study of CD19/BCMA-targeted CAR-T Cells Combined With Dasatinib for Patients With Relapsed and/or Refractory B-cell Acute Lymphoblastic Leukemia, B-cell Non-Hodgkin's Lymphoma and Multiple Myeloma.

Recruiting27 enrollment criteria

A Study of CTA30X Cell Injection in Patients With Relapsed or Refractory CD19-positive B-line Hematological...

Acute Lymphoblastic LeukemiaNon-hodgkin Lymphoma

A study of CTA30X cell injection in the treatment of relapsed or refractory CD19-positive B-line hematological malignancies

Recruiting44 enrollment criteria

BAFFR Targeting CAR-T Cells for the Treatment of Relapsed or Refractory B-cell ALL

Relapsed or Refractory B-cell Acute Lymphoblastic Leukemia

A Phase 1 Study Evaluating BAFFR-targeting CAR T Cells for Patients with Relapsed or Refractory B-cell Acute Lymphoblastic Leukemia

Recruiting49 enrollment criteria

Anti-CD5 CAR T Cells for Relapsed/Refractory T Cell Malignancies

T-cell Acute Lymphoblastic LeukemiaT-cell Non-Hodgkin Lymphoma

This is a phase I, interventional, single arm, open label, treatment study to evaluate the safety and tolerability of anti-CD5 CART cells in patients with relapsed and/or refractory T cell lymphoma or leukemia.

Recruiting9 enrollment criteria

Palbociclib in Combination With Chemotherapy in Pediatric Patients With Relapsed or Refractory Acute...

Acute Lymphoblastic LeukemiaPediatric2 more

With this research study has following goals To confirm the highest tolerable dose of palbociclib in combination with chemotherapy is safe and well-tolerated. To learn more about side effects of palbociclib in combination with chemotherapy; To learn more about the biological effects of palbociclib on the cells in your body

Recruiting39 enrollment criteria

Study to Evaluate the Role of Siltuximab in Treatment of Cytokine Release Syndrome (CRS) and Immune...

Cytokine Release SyndromeICANS4 more

This study will evaluate the use of siltuximab to decrease the severity of cytokine release syndrome (CRS) and immune effector cell-associated neurological syndrome (ICANS) in patients who will receive chimeric antigen receptor (CAR) T-cell therapy for the treatment of hematological malignancies.

Recruiting14 enrollment criteria

ALaCART-B: Acute Leukemia and Chimeric Antigen Receptor-T Cell Therapy for B-lymphoblastic Leukemia....

Lymphoblastic LeukemiaAcute7 more

The objective of this study is to assess the safety and efficacy of a immunophenotype-adapted approach using CAR T-cells in patients with high-risk, refractory or relapsed B-lineage acute lymphoblastic leukemia (B-ALL).

Recruiting27 enrollment criteria

Venetoclax in Combination With Non-myeloablative Conditioning Allogeneic Haematopoietic Stem Cell...

LeukemiaMyeloid12 more

This is a Phase 1, open-label, single center study of short-course oral venetoclax therapy prior to non-myeloablative conditioning with fludarabine and cyclophosphamide in subjects with haematological malignancies who are planned for allogeneic stem cell transplantation (alloSCT). The primary study objective is to determine the safety and maximum tolerated dose of venetoclax when used in combination with fludarabine and cyclophosphamide conditioning. Secondary objectives were to evaluate the transplant outcomes and donor/recipient engraftment of this regimen.

Recruiting35 enrollment criteria

NKX019, Intravenous Allogeneic Chimeric Antigen Receptor Natural Killer Cells (CAR NK), in Adults...

LymphomaNon-Hodgkin9 more

This is a single arm, open-label, multi-center, Phase 1 study to determine the safety and tolerability of an experimental therapy called NKX019 (allogeneic CAR NK cells targeting CD19) in patients with relapsed/refractory non-Hodgkin lymphoma (NHL), chronic lymphocytic leukemia (CLL) or B cell acute lymphoblastic leukemia (B-ALL)

Recruiting27 enrollment criteria

A Phase 1/2 Study of the Safety and Efficacy of Anti-CD7 Allogeneic CAR-T Cells (WU-CART-007) in...

T-cell Acute Lymphoblastic LeukemiaLymphoblastic Lymphoma

The main purpose of this study is to evaluate the safety, recommended dose, and preliminary anti-tumor activity of WU-CART-007 in patients with relapsed or refractory (R/R) T-cell acute lymphoblastic leukemia (T-ALL) or lymphoblastic lymphoma (LBL).

Recruiting29 enrollment criteria
1...456...182

Need Help? Contact our team!


We'll reach out to this number within 24 hrs